$289.9 M

OCUL Mkt cap, 22-Jun-2018

$340 K

Ocular Therapeutix Revenue Q1, 2018
Ocular Therapeutix Gross profit (Q1, 2018)260 K
Ocular Therapeutix Gross profit margin (Q1, 2018), %76.5%
Ocular Therapeutix Net income (Q1, 2018)-13.8 M
Ocular Therapeutix EBIT (Q1, 2018)-13.5 M
Ocular Therapeutix Cash, 31-Mar-201862.9 M

Ocular Therapeutix Financials

Ocular Therapeutix Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

772 k1.8 m1.9 m

Revenue growth, %

127%

Sales and marketing expense

17 m

R&D expense

30.9 m

General and administrative expense

15.5 m

Operating expense total

63.8 m

EBIT

(61.9 m)

EBIT margin, %

(3220%)

Interest expense

1.9 m

Interest income

424 k

Net Income

(28.6 m)(39.7 m)(44.7 m)(63.4 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

340 k

Cost of goods sold

80 k

Gross profit

260 k

Gross profit Margin, %

76%

Sales and marketing expense

717 k

R&D expense

8.2 m

General and administrative expense

4.8 m

Operating expense total

13.8 m

EBIT

(13.5 m)

EBIT margin, %

(3957%)

Interest expense

486 k

Interest income

176 k

Net Income

(13.4 m)(20.7 m)(7.6 m)(17.6 m)(29.1 m)(10.8 m)(22.3 m)(31.9 m)(16 m)(13.8 m)

Ocular Therapeutix Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

37.4 m30.8 m32.9 m41.5 m

Accounts Receivable

329 k193 k250 k226 k

Inventories

893 k1.6 m1.4 m122 k

Current Assets

76.2 m107 m69.9 m43.3 m

PP&E

1.8 m3.1 m3.3 m10.5 m

Total Assets

78.2 m110.3 m74.9 m55.4 m

Accounts Payable

1.3 m2 m2.1 m3.6 m

Current Liabilities

5.9 m5.4 m8.3 m13.4 m

Total Liabilities

22.9 m29.3 m

Additional Paid-in Capital

148.1 m218.8 m225.9 m263.4 m

Retained Earnings

(89.4 m)(129.2 m)(173.9 m)(237.3 m)

Total Equity

58.7 m89.6 m52 m26.1 m

Financial Leverage

1.3 x1.2 x1.4 x2.1 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

19.9 m80.9 m12.5 m78.7 m41.2 m46.2 m48.2 m52.2 m54.7 m63 m62.9 m

Accounts Receivable

60 k53 k352 k164 k189 k227 k223 k243 k244 k211 k170 k

Inventories

109 k117 k158 k145 k147 k127 k149 k126 k96 k90 k139 k

Current Assets

22.6 m82.3 m69.5 m126.6 m115.9 m97.1 m85 m76.8 m83.3 m68.3 m64.5 m

PP&E

1.2 m1.4 m1.8 m2.6 m3.2 m3.1 m3.2 m3.8 m5.7 m9.6 m10.6 m

Total Assets

24 m83.9 m71.5 m129.5 m119.3 m100.4 m89.9 m82.3 m90.7 m79.7 m76.7 m

Accounts Payable

1.5 m649 k2.2 m2.8 m1.6 m2.1 m1.6 m1.7 m3.8 m6.3 m3.5 m

Current Liabilities

4.5 m3.4 m7.2 m9.6 m11.2 m6 m6.4 m8.2 m8.7 m13.1 m13.2 m

Total Liabilities

19.1 m18.3 m19.4 m20.4 m20.5 m20.3 m19.5 m20.1 m26.8 m31.7 m27.5 m

Additional Paid-in Capital

4.7 m147.1 m149.1 m216.1 m217.4 m220.2 m221.9 m223.3 m253.8 m256.6 m300.2 m

Retained Earnings

(74.2 m)(81.5 m)(97 m)(107 m)(118.5 m)(140 m)(151.5 m)(161.1 m)(189.9 m)(208.6 m)(251 m)

Total Equity

(69.4 m)65.6 m52.1 m109.1 m98.8 m80.2 m70.4 m62.3 m63.9 m48 m49.2 m

Financial Leverage

-0.3 x1.3 x1.4 x1.2 x1.2 x1.3 x1.3 x1.3 x1.4 x1.7 x1.6 x

Ocular Therapeutix Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(28.6 m)(39.7 m)(44.7 m)(63.4 m)

Depreciation and Amortization

547 k754 k881 k1.6 m

Accounts Receivable

(79 k)136 k(57 k)24 k

Inventories

(36 k)(53 k)924 k(9 k)

Accounts Payable

507 k348 k(159 k)932 k

Cash From Operating Activities

(20.5 m)(33.7 m)(34 m)(50.5 m)

Purchases of PP&E

(1.3 m)(1.8 m)(1.9 m)(8.3 m)

Cash From Investing Activities

(38.6 m)(38.6 m)35.6 m27.1 m

Long-term Borrowings

(1.3 m)

Cash From Financing Activities

79 m65.7 m585 k32 m

Interest Paid

844 k1.3 m1.3 m1.5 m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(13.4 m)(20.7 m)(7.6 m)(17.6 m)(29.1 m)(10.8 m)(22.3 m)(31.9 m)(16 m)(34.7 m)(13.8 m)

Depreciation and Amortization

244 k383 k173 k360 k554 k205 k412 k628 k261 k615 k565 k

Accounts Receivable

190 k197 k(23 k)165 k140 k(34 k)(30 k)(50 k)6 k39 k56 k

Inventories

(109 k)(117 k)(25 k)(12 k)(14 k)7 k(15 k)8 k17 k23 k(17 k)

Accounts Payable

345 k63 k153 k651 k(360 k)79 k(462 k)(289 k)659 k2.9 m(662 k)

Cash From Operating Activities

(8.5 m)(14.9 m)(6.9 m)(15.4 m)(25.1 m)(9.3 m)(19.1 m)(26.4 m)(14.6 m)(25.7 m)(12.5 m)

Purchases of PP&E

(545 k)(819 k)(354 k)(1.2 m)(1.3 m)(127 k)(370 k)(1.2 m)(1.7 m)(5.7 m)(381 k)

Cash From Investing Activities

(545 k)(819 k)(17.9 m)(8.9 m)(36.5 m)24.9 m36.6 m47.9 m7.8 m26.5 m(381 k)

Long-term Borrowings

(1 m)

Cash From Financing Activities

11.5 m79.1 m(137 k)65.6 m65.4 m(189 k)(186 k)(108 k)28.5 m29.3 m34.2 m

Interest Paid

310 k625 k942 k688 k

Ocular Therapeutix Ratios

USDY, 2018

Financial Leverage

1.6 x
Report incorrect company information